Vericel Corp

Vericel Corp is a U.S.-based biopharmaceutical company focused on advanced therapies for cartilage repair and severe burn care. Its commercial portfolio includes MACI for knee cartilage defects, Epicel for severe burns, and NexoBrid for burn eschar removal in North America through a license and supply arrangement.

8,2 %

74,4 %

6,0 %

+16,5 %

5.03

4.68

— Vericel Corp
%
MACI75% Autologous cell therapy for repair of symptomatic knee cartilage defects.
Epicel15% Cultured epidermal autograft used for patients with severe burns.
NexoBrid5% Specialty biologic for enzymatic removal of burn eschar in burn care.
MACI Arthro and related instruments5% Arthroscopic delivery tools and accessories used with MACI implants.

Vericel sells primarily to hospitals, specialty pharmacies, burn centers, and surgeons that treat patients with...

  • Orthopedic surgeons and sports medicine centersprimary

    Buy and implant MACI for symptomatic knee cartilage defects, especially higher-volume arthroscopic surgeons.

  • Hospitals and specialty pharmaciesprimary

    Dispense MACI under payer authorization and manage billing/collection for patient-specific use.

  • Burn centers and hospital burn unitsprimary

    Use Epicel and NexoBrid for severe burn treatment and eschar removal.

  • Specialty distributorssecondary

    Purchase NexoBrid and resell it to hospitals and burn centers.

  • Military and institutional facilitiessecondary

    Buy MACI under contracted arrangements for treatment at military facilities.

Vericel’s operations are concentrated in the United States, where it manufactures, markets, and sells its products...

  • •All operations are located in the United States
  • •100% of revenue is derived from domestic sales
  • •Manufacturing is centered in Massachusetts
  • •Commercial activity is focused on U.S. hospitals, burn centers, and surgeons

Vericel’s strategy centers on expanding adoption of its commercial therapies, especially MACI, while broadening surgeon...

01
Expand MACI surgeon adoption and procedure volumeshort-term

MACI is the core commercial product and depends on surgeon training and procedural penetration.

02
Build burn care franchise around Epicel and NexoBridmedium-term

Burn care provides a second specialty channel with focused institutional customers.

03
Increase manufacturing capacity and operational resiliencemedium-term

Cell therapy products require reliable in-house production and validated facilities.

Vericel faces concentration risk in a small number of specialty products, with demand tied to surgeon adoption,...

critical

Manufacturing disruption or facility failure

Products are biologic therapies requiring controlled in-house production and supply continuity.

Scope
MACI and Epicel manufacturing in Massachusetts
Materiality
high
high

Quarterly and annual revenue volatility

Sales depend on procedure timing, seasonal patterns, and burn-care demand.

Scope
MACI, Epicel, NexoBrid
Materiality
high
high

Payer coverage and reimbursement risk

MACI shipments require prior authorization and reimbursement can vary by payer.

Scope
MACI
Materiality
high
high

Intellectual property and license dependence

Exclusive commercialization rights for NexoBrid depend on compliance with MediWound agreements.

Scope
NexoBrid
Materiality
high
medium

Commercial adoption risk for NexoBrid

The product must gain acceptance in a specialized burn-care market to scale meaningfully.

Scope
North America commercialization rights
Materiality
medium
medium

Competition from alternative cartilage and burn treatments

Established medical device and biologics companies compete in regenerative medicine and burn care.

Scope
MACI and Epicel
Materiality
medium
ASC 606 revenue recognition for MACI
Patient-specific reimbursement and denial rates affect reported sales
Contractual allowances and credit loss estimates
Can materially change net product revenue and receivables
Lease accounting for Massachusetts facilities
Affects operating expenses and balance sheet obligations
Valuation allowance on deferred tax assets
Can significantly affect tax expense and net income

NEXGEL, INC.

NXGL · Surgical & Medical Instruments & Apparatus

HEXCEL CORP /DE/

HXL · Plastic Materials, Synth Resins & Nonvulcan Elastomers

Nurix Therapeutics, Inc.

NRIX · Pharmaceutical Preparations

Axogen, Inc.

AXGN · Electromedical & Electrotherapeutic Apparatus

AVITA Medical, Inc.

RCEL · Surgical & Medical Instruments & Apparatus

VERU INC.

VERU · Pharmaceutical Preparations

: 29/04/2026